Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing small-molecule therapeutics derived from its boron chemistry platform. The companyÂ’s lead product programs include AN2690, a topical antifungal product candidate in Phase 3 clinical development for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor in Phase 2b clinical trial for the treatment of psoriasis and atopic dermatitis; and GSK 2251052, or GSK '052, a systemic antibiotic in Phase 2 clinical trial for the treatment of infections caused by Gram-negative bacteria. It also engages in developing AN2718, a topical antifungal product candidate, which completed Phase 1 clinical trial for the treatment of onychomycosis and skin fungal infections; and AN2898, a topical anti-inflammatory product candidate, which completed Phase 1 clinical trial for the treatment of psoriasis, and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

Sector & Industry Watch List